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Objectives: This study was undertaken to identify management strategies that
maximize survival of patients with stage III non–small cell lung cancer and
metachronous brain metastases and to determine whether any apparent improved
survival was due to treatment or simply to patient selection.
Methods: Treatment evaluations of both primary non–small cell lung cancer and
brain metastases were performed in 91 patients. Optimal treatment was identified by
multivariable analysis. Propensity scoring and multivariable analysis were used to
separate treatment benefit from patient selection.
Results: Risk-unadjusted median, 12-, and 24-month survivals were 5.2 months,
22%, and 10%, respectively. Younger age (P  .006), good performance status
(P  .003), stage IIIA (P  .001), lung resection (P  .02), no other systemic
metastases at time of diagnosis of brain metastases (P  .02), and either metasta-
sectomy (P  .001) or stereotactic radiosurgery (P  .001) predicted best survival.
However, metastasectomy or stereotactic radiosurgery was more common after lung
resection (P  .02) and in patients with good performance status (P  .006), no
other systemic metastases at time of diagnosis of brain metastases (P  .01), and
fewer brain metastases (P  .001), suggesting that the patients with the best risk
profile were selected for aggressive therapy of both lung primary and brain metas-
tases. Despite this selection, analysis of propensity-matched patients demonstrated
the benefit of lung resection and metastasectomy or stereotactic radiosurgery
(P  .001).
Conclusions: Younger patients with resected stage IIIA non–small cell lung cancer
who have isolated metachronous brain metastases and good performance status do
best when treated with metastasectomy or stereotactic radiosurgery. This survival
benefit is a brain treatment effect, not the result of selecting the best patients for
aggressive therapy.
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As early as the 1970s, clinical reports sug-gested that aggressive therapy provided asurvival advantage for highly selected pa-tients with non–small cell lung cancer(NSCLC) and brain metastases.1,2 Neoad-juvant therapy for stage III NSCLC has
produced a unique cohort of patients who have survived to
have metachronous brain metastases develop.3 Optimal
management in these cases is uncertain,4 a difficulty that
provided the impetus for this study. The purposes of this
study were to identify management strategies that maximize
survival of patients with stage III NSCLC and metachro-
nous brain metastases and to determine whether any appar-
ent improved survival was due to treatment or simply pa-
tient selection.
Patients and Methods
Patients
From review of the Cleveland Clinic Foundation hospital dis-
charge database, Cancer Center Registry, and Radiation Oncology
Registry, 91 patients were identified with metachronous brain
metastases after a diagnosis of stage IIIA or IIIB NSCLC. Meta-
chronous brain metastasis was considered to be a brain metastasis
occurring 3 or more months after diagnosis of the primary NSCLC.
Brain metastases were confirmed by computed tomography, mag-
netic resonance imaging, or both. Stage IIIA or IIIB NSCLC was
Tany N2 M0, Tany N3 M0, or T4 Nany M0 (excluding malignant
pleural effusions and separate tumor nodules in the same lobe)
documented by mediastinoscopy (n  48), thoracotomy (n  9),
or computed tomography (n  34).
Cross-sectional systematic follow-up was done in February
2001. Eighty-three patients were dead. Mean follow-up was 36
months (range 2.5 to 96 months) for 8 living patients. Time zero
for time-related analysis was measured from diagnosis of meta-
chronous brain metastases. All-cause mortality was the study end
point.
Data Analysis
Identification of optimal management. The goal of assessing
management was identification of strategies that maximized sur-
vival. Nonparametric estimates of survival after development of
brain metastases were obtained using the Kaplan–Meier method.
Parametric estimates of survival were obtained by hazard function
analysis.5 Survival estimates were compared between subgroups
using the log-rank test.
Both multivariable Cox proportional hazards analysis and para-
metric hazard function analysis of all variables listed in Appendix
Table A were used to identify risk factors for death after devel-
opment of brain metastases. A stepwise selection procedure was
used, with a P  .05 criterion for retention of variables in the final
model. This procedure was verified by bootstrap bagging with
1000 samples.6 Variables identified in at least 50% of the bootstrap
analyses were considered reliable. Continuous and ordinal vari-
ables were assessed univariably by decile risk analysis to deter-
mine whether their relationship was well calibrated to model
outcome or whether transformations of scale were required.
Treatment benefit or patient selection? Because there was no
treatment protocol, patient selection itself could lead to spurious
conclusions that certain therapies improved survival. At the same
time, the resulting variance in management permitted separation of
treatment effect from that of patient selection by means of pro-
pensity score matching.7 The propensity model included 10 vari-
ables: gender, histologic type, stage at treatment of NSCLC, lung
resection (vs none) for NSCLC, disease-free interval, number of
brain metastases, local recurrence of NSCLC, presence of distant
metastases other than in the brain, Eastern Cooperative Oncology
Group (ECOG) performance status at diagnosis of brain metasta-
ses, and a recursive partitioning analysis (RPA) score. (RPA score
ranges from 1 to 3 and is composed of age, performance status,
recurrence of NSCLC, and presence of other distant metastases.8)
All these variables were entered into a multivariable logistic re-
gression model of metastasectomy or stereotactic radiosurgery
versus palliation. For each patient, the model was used to calculate
the probability of undergoing metastasectomy or stereotactic ra-
diosurgery. This probability is the propensity score.
The propensity score was used in two ways to separate treat-
ment from selection effects. First, we used it to compare survival
benefit of metastasectomy or stereotactic radiosurgery within
propensity-matched groups. For this, patients were sorted accord-
ing to the propensity score and divided into two equal-sized
groups. We then determined the effect of metastasectomy or ste-
reotactic radiosurgery on survival within each of the groups using
the Kaplan–Meier method and log-rank test. To assess similarity
within each group, t tests and contingency tables were used to
compare patient factors, tumor factors, and treatment of NSCLC
between patients who underwent metastasectomy or stereotactic
radiosurgery and those who did not.
Second, the propensity score was used to confirm the results of
the multivariable analysis that metastasectomy or stereotactic ra-
diotherapy was beneficial.9 For this, the propensity score was
incorporated into the multivariable survival model of optimal
management, and its adjustment of treatment effect magnitude and
statistical significance was observed.
Presentation. Hazard and odds ratios are accompanied by 95%
confidence intervals (CIs). Depiction of the ideal candidate for
metastasectomy or stereotactic radiosurgery and the ideal candi-
date for palliation of brain metastases used the hazard function
analysis. Specific values were entered into the multivariable equa-
tion, the equation was solved, and results were presented graphi-
cally with 68% CIs equivalent to 1 SE.
Results
Identification of Optimal Management
Characterization and treatment of NSCLC. Fifty-two
patients (57%) had stage IIIA NSCLC. Tumor histologic
type was squamous cell carcinoma in 25 patients (27%),
adenocarcinoma in 50 (55%), and large cell carcinoma in 16
(18%). NSCLC was not treated in 3 patients (3%) because
of treatment refusal in 1 patient and prohibitive comorbidi-
ties in 2. Treatment was chemoradiation therapy only in 29
patients (32%). Surgery was used in 59 patients (65%):
resection in 11 (12%), resection and postoperative adjuvant
therapy in 22 (24%), and neoadjuvant therapy (chemoradia-
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tion and surgery) in 26 (28%). Resection was segmentec-
tomy in 2 patients (2%), lobectomy in 35 patients (38%),
and pneumonectomy in 22 patients (24%).
Characterization and treatment of brain metastases.
Forty-two patients (46%) had a single brain metastasis, 15
(16%) had 2 metastases, 16 (18%) had 3, and 18 (20%) had
4 or more. Sixty-two patients (68%) had unilateral brain
metastases. Treatment of brain metastases was whole-brain
radiation therapy in 43 patients (47%), metastasectomy
alone or in combination with whole-brain radiation therapy
in 23 patients (25%), and stereotactic radiosurgery with or
without whole-brain radiation therapy in 24 patients (26%).
One patient received no treatment.
The impact of stage III NSCLC and its treatment on
metachronous brain metastases is described in Appendix A.
Optimal management. Risk-unadjusted survivals at 3,
6, 12, and 24 months after diagnosis of metachronous brain
metastases were 70%, 45%, 22%, and 10%, respectively,
with a median survival of 5.2 months (Figure 1). Risk
factors for death are listed in Table 1. Good survival was
predicted by stage IIIA, resection of NSCLC, younger age
at diagnosis of brain metastases, good performance status,
no other distant metastases, and metastasectomy or stereo-
tactic radiosurgery (Figure 2 and Appendix Figure A).
Figure 1. Risk-unadjusted survival. Vertical bars represent pa-
tients alive at last follow-up. Survival estimates  SE and num-
bers of patients remaining at risk at 6, 12, and 24 months were
45%  5.3% (n  40), 22%  4.4% (n  19), and 10%  3.3% (n 
8), respectively.
Figure 2. Survival according to treatment of metachronous brain
metastases. Figure format as in Figure 1. Survival estimates  SE
and numbers of patients remaining at risk at 6, 12, and 24 months
were as follows: for metastasectomy (MET, solid line, n  23),
77% 8.9% (n 17), 39% 10.6% (n 8), and 29% 10.0% (n
6), respectively; for stereotactic radiosurgery (SRS, dashed line,
n  24), 65%  9.9% (n  15), 39%  10.2% (n  9), and 13% 
7.0% (n  3), respectively; and for palliation (unevenly broken
line, n 44), 18% 5.8% (n 8), 5% 3.1% (n 2), and 0% (n
0), respectively.
Figure 3. Comparison of metastasectomy or stereotactic radiosur-
gery (MET/SRS) with palliation in patients with characteristics
predictive of good survival (A) and poor survival (B). A, 45-year-
old patient with stage IIIA NSCLC treated by pneumonectomy. At
diagnosis of metachronous brain metastases, this patient has
ECOG 0 to 1 status with no other systemic metastases. B, 65-year-
old patient with stage IIIB NSCLC not resected. At diagnosis of
metachronous brain metastases, this patient has ECOG 2 status
with other systemic metastases.
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.Figure 3 illustrates four combinations of patients and
treatment of brain metastases. Figure 3, A, demonstrates the
clinically important survival benefit of metastasectomy or
stereotactic radiosurgery relative to palliation for metachro-
nous brain metastases in a patient with characteristics pre-
dictive of good survival. Figure 3, B, demonstrates the
statistically significant but clinically unimportant survival
benefit of metastasectomy or stereotactic radiosurgery rela-
tive to palliation for metachronous brain metastases in a
patient with characteristics predictive of poor survival.
Treatment Benefit or Patient Selection?
Multivariable analysis of factors associated with metasta-
sectomy or stereotactic radiosurgery demonstrated patient
selection (Table 2 and Appendix B). Two propensity-
stratified groups addressed this patient selection (Table 3).
Group 1 consisted predominantly of patients with charac-
teristics predictive of good survival, most of whom were
treated with metastasectomy or stereotactic radiotherapy. A
small number received palliation. In contrast, group 2 was
predominantly patients with characteristics predictive of
poor survival, most of whom received palliation. A small
number underwent metastasectomy or stereotactic radio-
therapy. In both groups a survival advantage of metastasec-
tomy or stereotactic radiosurgery with respect to palliation
was demonstrated (Figure 4).
Optimal Management Revisited
Adding propensity score (P  .3) to the multivariable
analysis of death confirmed the survival benefit of metasta-
sectomy (P  .0001) or stereotactic radiosurgery (P 
.0003) and thus the inferences concerning optimal manage-
ment.
Discussion
Optimal Management
Patients with untreated NSCLC brain metastases die of
progressive neurologic deterioration within 1 month.10 Sur-
vival and quality of life for patients with solitary brain
metastases are superior when metastasectomy is included in
the treatment.11 However, complete resection of the primary
lung cancer and control of the primary and other distant
extracranial metastatic sites determine outcome after brain
metastasectomy (Appendices A and B).
Solitary brain metastasis has been a selection factor for
metastasectomy; however, many patients have more than
one brain metastasis.10,12 This and other selection factors
have produced a literature of treatment of brain metastases
in highly selected patients. Many readers attribute good
survival to a given treatment; however, it may actually be
due to patient selection. Thus, although it is intuitively
apparent that some patients will benefit from aggressive
treatment of their brain metastases, it remains unclear which
patients should be treated and how. Optimal treatment of
patients with NSCLC brain metastases cannot be general-
ized, because they are heterogeneous and treatment must be
individually selected.
TABLE 1. Risk factors for death after diagnosis of brain metastases
Risk factor Coefficient P value Reliability*
Lung cancer
Stage IIIB vs IIIA 0.83 0.26 .001 69%
No resection of lung cancer 0.73 0.25 .004 55%
Brain metastases
Older age at diagnosis of brain metastases 0.038 0.0147 .009 68%
Worse ECOG performance status† 0.36 0.088 .0001 93%
Presence of other systemic metastases 1.04 0.33 .002 53%
Treatment of brain metastases
No resection of brain metastases 1.64 0.36 .0001 96%
No stereotactic radiosurgery 1.11 0.32 .0005
Earlier date of treatment‡ 0.34 0.140 .01 62%
Coefficients are  SE.
*Frequency of appearance in 1000 bootstrap analyses (see Methods section).
†ECOG classes 0 and 1 combined as class 0, ECOG class 2 as class 1, and ECOG class 3 as class 2, squared transformation.
‡Derived as ln [date of treatment (in years since June 1, 1980)], natural logarithmic transformation.
}
TABLE 2. Correlates of metastasectomy or stereotactic
radiosurgery for brain metastases
Correlate Odds ratio 95% CI P value
Resection of lung cancer
Yes vs no 4.0 1.3-13 .02
ECOG performance status
Per 1-pt increase 0.26 0.10-0.68 .006
Other systemic metastases
Absent vs present 9.1 1.6-50 .01
No. of brain metastases
Per 1-metastasis increase 0.4 0.24-0.66 .001
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One aspect of heterogeneity is stage of primary NSCLC.
Neoadjuvant treatment of stage III NSCLC produces a
unique cohort of patients who have the primary NSCLC
controlled and survive to have brain metastases develop.3
Another aspect is the method of treatment of the brain
metastases. Although no phase III trials comparing metas-
tasectomy with stereotactic radiosurgery have been com-
pleted, our report and others have demonstrated similar
survivals between these modalities.13-15 Only technical con-
siderations (large metastasis and neurologic deterioration
from mass effect) limit the use of stereotactic radiosurgery.
In this report, both metastasectomy and stereotactic ra-
diosurgery produced a survival advantage relative to whole-
brain radiation or symptomatic therapy (palliation). For the
patient with characteristics predictive of poor survival, this
advantage was statistically significant but clinically unim-
portant. Therefore, in such patients quality of life becomes
the goal of therapy. Stereotactic radiosurgery spares the
patient the trauma of metastasectomy and may provide the
best palliation. Whole-brain radiation therapy should be
reserved for patients who are not candidates for stereotactic
radiosurgery.
For the patient with characteristics predictive of good
survival—younger age (Appendix Figure A), previous re-
section of NSCLC, stage IIIA, good performance status
at diagnosis of brain metastasis, and no other distant
metastases—survival was better if cure rather than pallia-
tion was the goal. The “good-risk” patient is denied long-
term survival if treated with palliative intent using only
whole-brain radiation or symptomatic therapy. Because of
equivalent survivals with metastasectomy and stereotactic
radiosurgery in these patients and the lack of any phase III
trials, there is uncertainty—even among ourselves—about
which of these two modalities should be offered to which
patient.
Treatment Benefit or Treatment Selection?
Lack of a management protocol produced variations in
treatment and thus provided a spectrum of patient–therapy
combinations. A patient with characteristics predictive of
good survival was more likely to be selected for metasta-
sectomy or stereotactic radiosurgery, whereas a patient with
characteristics predictive of poor survival was more likely
to be selected for whole-brain radiotherapy or symptomatic
TABLE 3. Comparisons within propensity-matched groups
Variable
Group 1 (good survival) Group 2 (poor survival)
Palliation Treatment*
P value
Palliation Treatment*
P value(n  6) (n  40) (n  38) (n  7)
Demographics
Male (%) 50 58 .7 53 43 .6
Primary NSCLC
Histologic type (%)
Squamous cell 33 28 .6 24 43 .16
Adenocarcinoma 33 52 66 29
Large cell 33 20 11 29
Stage IIIA (%) 50 55 .8 63 43 .3
Resection of lung cancer (%)
None 17 22 .9 53 29 .5
Segmentectomy and lobectomy 50 40 37 57
Pneumonectomy 33 38 11 14
Brain metastases
Disease-free interval (mo) 8.6 5.5 14.9 12.4 .2 10.6 8.4 6.2 2.5 .17
Age at diagnosis (y) 61 6 57 9 .4 62 10 60 11 .6
ECOG performance status (%)
0 0 2 .5 0 14 .08
1 100 82 39 43
2 0 15 42 43
3-4 0 0 18 0
Primary NSCLC recurrence (%) 17 18 .96 58 43 .5
Other systemic metastases (%) 17 5 .3 26 14 .5
Recursive partitioning analysis score (%)
1 50 62 .6 5 14 .4
2 50 38 58 71
3 0 0 37 14
No. of brain lesions (mean  SD) 1.8 1.3 1.5 0.8 .3 2.8 1.2 2.6 1.1 .7
Unilateral brain metastases (%) 83 92 .5 47 29 .4
*Treatment was either metastasectomy or stereotactic radiosurgery.
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therapy. Propensity score methodology was developed to
address nonrandomized comparisons in which therapy has
not been applied either randomly or systematically.7,9
Use of the propensity score in this study allowed patient
selection to be separated from treatment effect. We used
propensity scores in two ways in the analysis. First, we
found in propensity-matched patients a uniform benefit of
treating metachronous brain metastases with metastasec-
tomy or stereotactic radiosurgery. Second, we introduced
the propensity score into the multivariable analysis of op-
timal treatment and confirmed the benefit of metastasec-
tomy or stereotactic radiosurgery. Both analyses demon-
strated a clinically significant benefit only for the good-risk
patient.9
Limitations
This was a small, single-institution clinical experience. The
study required that all patients survive to develop brain
metastases, making interim death a selection factor. Patients
were selected for treatment by clinical criteria; treatment
was administered in a nonrandom fashion. To limit the
influence of nonrandomization, we used propensity scores
as described previously. Despite our use of 10 variables to
develop the score and produce well-matched groups, the
propensity score did not match for unrecorded variables that
may have influenced selection.
Conclusion
Younger patients with resected stage IIIA NSCLC who
have isolated metachronous brain metastases and good per-
formance status do best when treated with metastasectomy
or stereotactic radiosurgery. Survival benefit is a brain treat-
ment effect and not the result of selecting the best candi-
dates for aggressive therapy.
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Appendix A
Impact of Stage III Non–Small Cell Lung Cancer and
Its Treatment on Metachronous Brain Metastases
In this nonrandomized clinical experience, characteristics and
treatment of the primary lung cancer varied. These factors may
have influenced both development and treatment of metachronous
brain metastases.
Stage III Non–Small Cell Lung Cancer
Time interval between treatment of NSCLC and diagnosis of brain
metastases was highly variable. According to multivariable anal-
ysis, longer disease-free intervals were seen in men (hazard ratio
0.55, 95% CI 0.35-0.86, P  .009), for squamous cell carcinoma
versus large cell undifferentiated carcinoma (hazard ratio 0.47,
95% CI 0.24-0.91, P  .02), for adenocarcinoma versus large cell
carcinoma (hazard ratio 0.58, 95% CI 0.33-1.03, P  .06), and in
patients who had undergone pneumonectomy (hazard ratio 0.61,
95% CI 0.37-1.0, P  .05).
Patients who had undergone pneumonectomy had fewer brain
metastases (n 18/22 [82%] with 1 or 2 brain metastases) than did
those who had undergone segmentectomy or lobectomy (n 
20/37 [54%] with 1 or 2 brain metastases, P  .03). Unilateral
brain metastases were present in 21 patients who had undergone
pneumonectomy (95%) and in only 24 who had undergone seg-
mentectomy or lobectomy (65%, P  .008). Bilateral brain me-
tastases were more common among patients who did not undergo
resection of NSCLC (n  15/32, 47%) than among patients who
had resection (n  14/59, 24%, P  .02). However, the numbers
of brain metastases in these two groups were similar (P  .6).
Other distant metastases were more frequent at the time of diag-
nosis of brain metastases among patients who had undergone
resection of NSCLC (n  12/59, 20%, vs n  2/32, 6%, P  .08).
Treatment of Stage III Non–Small Cell Lung Cancer
Patients who had undergone resection only of NSCLC had a
similar number of brain metastases (n  8/11 [73%] with 1 or 2
brain metastases) to those who had also undergone postoperative
adjuvant or neoadjuvant therapy (n  30/48 [62%] with 1 or 2
brain metastases, P  .5). These two groups of patients were
similar in demographic characteristics, tumor factors, and treat-
ment of brain metastases (Appendix Table B).
Men were more likely to have undergone pneumonectomy (n
14/22, 64%) than lobectomy or segmentectomy (n  15/37, 41%,
P  .09).
Sites of active tumor found at death differed with treatment of
NSCLC. Among 32 patients without resection, sites of cancer were
locoregional (lung) in 25 cases (78%), brain in 21 (66%), and other
distant metastases in 9 (28%). In contrast, among 32 patients with
segmentectomy or lobectomy, sites of cancer were locoregional in
14 cases (44%), brain in 18 (56%), and other distant metastases in
7 (22%). Among 19 patients with pneumonectomy, sites of cancer
were locoregional in 7 cases (37%), brain in 8 (42%), and other
distant metastases in 8 (42%).
Appendix B
Factors Influencing Treatment of Brain Metastases
No clear pattern of treatment of brain metastases emerged over
time. However, treatment varied with age, with younger patients
likely to undergo metastasectomy, somewhat older patients likely
to undergo stereotactic radiotherapy, and the oldest patients likely
to undergo whole-brain radiation therapy (Appendix Table A).
Treatment also varied with disease-free interval. Disease-free
intervals were longest for patients who had metastasectomy,
shorter for those receiving stereotactic radiosurgery, and shortest
for those receiving palliation.
Treatment varied with the number of brain metastases. Two or
fewer brain metastases were seen in 87% of patients who had
metastasectomy, in 75% who had stereotactic radiosurgery, and in
Appendix Figure A. Predicted 1-year survival according to age of
patient having undergone pneumonectomy, with ECOG 0 to 1 and
no other systemic metastases at time of diagnosis of metachro-
nous brain metastases. Multivariable equation has been solved
for either metastasectomy or stereotactic radiosurgery (MET/SRS)
or palliation. Dashed lines represent 68% confidence intervals. A,
Stage IIIA NSCLC. B, Stage IIIB NSCLC.
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43% who had palliation. Unilateral brain metastases were more
likely to be treated with metastasectomy (87%) or stereotactic
radiosurgery (79%) than with palliation (52%). NSCLC was con-
trolled in 92% of patients receiving stereotactic radiosurgery, in
65% undergoing metastasectomy, and in 48% receiving palliation.
Other distant metastases were present in 4% of patients receiving
stereotactic radiosurgery and in 9% undergoing metastasectomy,
but in 25% receiving palliation.
Discussion
Dr Raphael Bueno (Boston, Mass). Moazami and colleagues,
in this comprehensive manuscript from the Cleveland Clinic, eval-
uated the treatment of metachronous brain metastases in patients
with locally advanced lung cancer. They found that younger pa-
tients with stage IIIA lung cancer who had previously been treated
with aggressive locoregional control of the primary cancer derived
substantial survival benefit from an aggressive treatment of the
brain metastases. They further found that survival after stereotactic
radiosurgery and metastasectomy might be equivalent for patients
with metastases smaller than 4 cm and better than after palliative
radiation. Their results also suggest that the brain is occasionally
the only site of metastasis in patients with resected N2-positive
stage IIIA lung cancer, a finding that is consistent with other
observations in the field of lung cancer as well as with our recent
analysis of patients treated for stage IIIA lung cancer with multi-
modal therapy. The take-home message from this article is that it
is reasonable to be aggressive when treating patients with good
performance and locoregional control of the lung cancer who have
isolated brain metastases.
I would like to pose a few questions. First, please tell us more
about the long-term survivors. Were they all young patients with
resected stage IIIA disease and single brain metastases, or are there
some older ones in the group? Also, perhaps we should use
functional status rather than age in the treatment algorithm, be-
cause even though posttreatment survival in your series was a little
worse among elderly patients, there is no other effective therapy.
Second, do you currently ever treat patients with stage IIIB
lung cancer with aggressive brain resection since the analysis of
your results? If so, why?
Appendix Table A. Treatment of brain metastases
Variable/group
Palliation*
(n  44)
Metastasectomy
(n  23)
Stereotactic
radiosurgery
(n  24)
P for palliation vs
metastasectomy and
stereotactic radiosurgery
P for metastasectomy vs
stereotactic
radiosurgery
Demographics
Male (no.) 23 (52%) 14 (61%) 12 (50%) .7 .4
Primary NSCLC
Histologic type (no.)
Squamous cell 11 (25%) 10 (44%) 4 (17%) .09 .04
Adenocarcinoma 27 (61%) 7 (30%) 16 (67%)
Large cell 6 (14%) 6 (26%) 4 (17%)
Stage IIIA (no.) 27 (61%) 11 (48%) 14 (58%) .6 .5
Resection of lung cancer (no.)
None 21 (48%) 4 (17%) 7 (29%) .07 .6
Segmentectomy or lobectomy 17 (39%) 11 (48%) 9 (38%)
Pneumonectomy 6 (14%) 8 (35%) 8 (33%)
Treatment of lung cancer (no.)
Palliation† 21 (48%) 4 (17%) 7 (29%) .13 .5
Resection only 4 (9%) 3 (13%) 4 (17%)
Resection with adjuvant therapy 19 (43%) 16 (70%) 13 (54%)
Brain metastases
Disease-free interval (mo) 10.4 8.0 16.0 14.0 11.3 9.1 .10 .18
Age at diagnosis (y) 62 10 56 10 59 9 .04 .2
ECOG performance status (no.)
0-1 21 (48%) 19 (83%) 19 (79%) .008 .8
2 16 (36%) 4 (17%) 5 (21%)
3-4 7 (16%) 0 (0%) 0 (0%)
Primary NSCLC recurrence (no.) 23 (52%) 8 (35%) 2 (8%) .002 .03
Other systemic metastases (no.) 11 (25%) 2 (9%) 1 (4%) .04 .55
Recursive partitioning analysis score (no.)
1 5 (11%) 11 (48%) 15 (62%) .001 .4
2 25 (57%) 11 (48%) 9 (38%)
3 14 (32%) 1 (4%) 0 (0%)
No. of metastases, 1 or 2 (no.) 19 (43%) 20 (87%) 18 (75%) .001 .3
Unilateral brain metastases (no.) 23 (52%) 20 (87%) 19 (79%) .006 .5
*Palliation for brain metastases consisted of 1 patient who received no treatment and 43 who received whole-brain radiotherapy alone.
†Palliation for lung cancer consisted of 3 patients who received no treatment and 29 who received chemoradiotherapy.
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Third, what is your denominator for this study, first in terms of
all patients treated at your institution with stage III lung cancer and
second in terms of all patients with stage III cancer who had distant
metastases develop? How many of those are just in the brain?
Fourth, are isolated brain metastases the most common first site
of failure in your institution for stage III lung cancer? We and
others have noted that, with a rate greater than 50% in our series.
If that is the case, should we consider prophylactic whole-brain
radiation for patients who undergo resection of stage IIIA lung
cancer?
Finally, how do you currently treat a patient with a T1 N2 M1
NSCLC whose only synchronous metastatic focus is an isolated 2
cm brain metastasis?
Dr Moazami. Dr Bueno, thank you for your comments. I will try
to address your questions in the order that you have addressed them.
You asked about the long-term survivors in this study. We had
a total of 91 patients, 8 of whom were alive at the end of our
follow-up period, which was completed in February 2001. Mean
follow-up of the patients was 36 months. Their mean age was 48
years (range 36-61 years). As you suggested, the patients in the
survival group actually correlated well with the variables that we
identified for best survival; that is, they were generally younger
patients with good performance status and controlled stage IIIA
disease in whom we had not detected any distant metastases other
than in the brain.
Your second question was whether we would aggressively treat
the brain lesion in a patient with stage IIIB given the results of our
data. I think that in general the results of all retrospective studies
such as this provide us with some guidelines, but obviously treat-
ment needs to be considered on a patient-to-patient basis. For a
patient with stage IIIB NSCLC that has been aggressively treated
with good locoregional control, we believe that it is reasonable to
proceed with aggressive treatment of an isolated brain lesion with
either resection or perhaps stereotactic radiosurgery. Future studies
should clarify whether stereotactic radiosurgery or metastasectomy
is the better treatment. Again, one of the purposes of this extensive
analysis was to show that, regardless of other factors, metastasec-
tomy or stereotactic radiosurgery does confer a survival benefit on
these patients.
You asked about the denominator of the study. We did an
extensive review of all the medical records at the Cleveland Clinic
during this 10-year period to try to select all the patients diagnosed
with stage III NSCLC. The total number of patients was 891. Of
those, we selected only the patients who had metachronous brain
metastases develop, which we considered as 3 months from the
time of diagnosis of lung cancer. This gave us the numerator,
which was 91 patients.
You asked whether we believe that the brain is commonly the
isolated site of failure and whether prophylactic whole-brain radi-
ation therapy should be given to this patient population. We
Appendix Table B. Resection versus resection and adjuvant therapy for the primary NSCLC
Resection alone
(n  11)
Resection plus adjuvant
therapy (n  48) P value
Demographics
Male (no.) 7 (64%) 22 (46%) .3
Primary NSCLC
Histologic type (no.)
Squamous cell 4 (36%) 10 (21%) .15
Adenocarcinoma 7 (64%) 26 (54%)
Large cell 0 (0%) 12 (25%)
Stage IIIA (no.) 7 (64%) 29 (60%) .8
Resection, pneumonectomy (no.) 5 (45%) 17 (35%) .5
Brain metastases
Disease-free interval (mo) 13.3 16.7 11.9 8.1 .7
Age at diagnosis of brain metastases (y) 60 11 58 10 .6
ECOG performance status (no.)
0-1 9 (82%) 32 (67%) .3
2 1 (9%) 14 (29%)
3-4 1 (9%) 2 (4%)
Control of primary NSCLC (no.) 8 (73%) 38 (79%) .6
Other systemic metastases (no.) 3 (27%) 9 (19%) .5
Recursive partitioning analysis score (no.)
1 4 (36%) 20 (42%) .9
2 5 (45%) 21 (44%)
3 2 (18%) 7 (15%)
No. of metastases 1 or 2 (no.) 8 (73%) 30 (62%) .5
Unilateral brain metastases (no.) 8 (73%) 37 (77%) .8
Treatment of brain metastases (no.)
Palliation 4 (36%) 19 (40%) .8
Metastasectomy 3 (27%) 16 (33%)
Stereotactic radiosurgery 4 (36%) 13 (27%)
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similarly found that in our study group, 46% of these patients had
an isolated brain metastasis. Whether we should prophylactically
radiate the brain has not been clarified in the literature. Most of the
studies that I am aware of have not shown any benefit of prophy-
lactic whole-brain radiation in any of the populations, with the
possible exception of those with small cell cancer.
Finally, you asked about a patient with a stage IIIA disease, T1
N2 M1, who has only a synchronous brain metastasis. Obviously,
the study was not meant to address synchronous brain metastases.
However, we believe that once an aggressive approach to locore-
gional control is established, it is also reasonable to proceed with
an aggressive treatment regimen for the brain. How to proceed in
treating a patient like this depends on the variables we have
discussed, including performance status.
Dr Robert J. Ginsberg (Toronto, Ontario, Canada). You had
8 long-term survivors. How many had 2 or more brain metastases?
Dr Moazami. Of the 8 survivors, 5 had 1 brain metastasis, 1
had 2 metastases, and 2 had 3 metastases.
Dr Ginsberg. Why was it not one of your conclusions that you
should limit this aggressive therapy to single metastases?
Dr Moazami. Well, there was a sharp cutoff in survival when we
divided the patients according to 1 to 2 brain metastases versus 3 or
more. In our conclusion we stated that the best candidates are the ones
that need to be aggressively treated. In this best profile that we
constructed, one factor was the presence of 1 to 2 metastases.
Dr Ginsberg. But you did not differentiate between 1 versus 2?
Dr Moazami. There was no difference in survival between
patients with 1 or 2 brain metastases. Predicted Kaplan-Meier
median survival was 6.3 months for 1 brain metastasis and 7.3
months for 2 brain metastases.
Dr Ginsberg. Were any patients with 2 metastases treated with
surgery?
Dr Moazami. Of 15 patients with 2 brain metastases, 7 had
palliative whole-brain radiotherapy, 4 had stereotactic radiother-
apy, and 4 had resection with whole-brain radiotherapy.
Dr Douglas E. Wood (Seattle, Wash). How do you feel that
you corrected for selection bias in the second half of your analysis,
that is, that the factors you identified, in vanishingly smaller
numbers, represent a treatment effect as opposed to a selection
effect of patients? And do you believe that the success in the
aggressively treated patients was due to systemic tumor control or
improved palliation within the brain?
Dr Moazami. The issue of selection bias was a concern. We tried
to address it as best we could by using the statistical method of
propensity matching. This allowed us to assign a propensity score on
the basis of the 10 variables and match the patients. It was our best
statistical tool to determine from this retrospective data analysis
whether the treatment was effective. Prospective, randomized studies
are another way to address such questions.
The data suggest that the patients who were aggressively
treated had control both locoregionally and in the brain. Most
failures were at distant sites.
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